摘要
目的 探讨纤维蛋白原联合中性粒细胞与淋巴细胞比值(NLR)所建立的新型预测模型(F-NLR评分)在接受新辅助治疗的食管鳞癌患者中的预后价值及其与病理学完全缓解(pCR)的关系.方法 收集2012-2015年218例在例郑州大学附属肿瘤医院接受新辅助治疗并符合入组条件的食管癌患者资料,根据ROC曲线求得血浆纤维蛋白原和NLR的最佳临界值,并以此计算F-NLR评分.观察不同F-NLR评分对生存及pCR的影响.采用Kaplan-Meier法生存分析,Wilcoxon秩和检验评估纤维蛋白原、NLR与pCR之间关系.结果 F-NLR评分0、1、2患者3年总生存率分别为72.1%、66.5%、50.2%(P=0.010),3年无瘤生存率分另为64.1%、60.2%、45.4% (P=0.012).F-NLR评分2者的预后明显差于评分0~1者(P=0.003).多因素分析显示F-NLR评分(P=0.004)和TNM分期(P=0.000)是预后影响因素.结论 F-NLR评分可用于预测接受新辅助治疗的食管鳞癌患者的预后,有希望作为临床常用TNM分期系统的补充,从而有助于更准确地对患者进行危险分层,以实现个体化多学科治疗.
Objective To evaluate the prognostic value of a novel prediction model based on fibrinogen concentration in combination with neutrophil-to-lymphocyte ratio (F-NLR score) in patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant therapy and investigate their relationship with pathologic complete response (pCR).Methods Clinical data of 218 eligible ESCC patients treated with neoadjuvant therapy in the Affiliated Cancer Hospital of Zhengzhou University between 2012 and 2015 were retrospectively analyzed.The cut-off values for fibrinogen and neutrophil-to-lymphocyte ratio (NLR)were defined by the receiver operating characteristic (ROC) curve.The effects of different F-NLR scores on survival and pCR were evaluated.The survival rate was analyzed using the Kaplan-Meier method.The relationship among fibrinogen,NLR and pCR was analyzed by using Wilcoxon rank sum test.Results The 3-year overall survival (OS) rates with F-NLR scores of 0,1 and 2 were 72.1%,66.5% and 50.2%(P=0.010),respectively.The corresponding 3-year disease-free survival (DFS) rates were 64.1%,60.2% and 45.4% (P=0.012),respectively.The clinical prognosis of patients with an F-NLR score of 2 was significantly worse compared with those of their counterparts with an F-NLR score of 0-1 (P=0.003).Multivariate analysis demonstrated that the F-NLR score (P=0.004) and TNM stage (P=0.000) were the independent prognostic factors.Conclusions The F-NLR score can be used as an independent prognostic factor for ESCC patients treated with neoadjuvant therapy,which is promising supplement to current TNM staging system,thereby facilitating more accurate risk stratification analysis and achieving individualized multidisciplinary treatment for ESCC patients.
作者
冯卓
罗辉
孙亚楠
刘晓
李雪
崔莹莹
汪晨宇
郑晓丽
王浩
叶柯
范诚诚
葛红
Feng Zhuo;Luo Hui;Sun Yanan;Liu Xiao;Li Xue;Cui Yingying;Wang Chenyu;Zheng Xiaoli;Wang Hao;Ye Ke;Fan Chengcheng;Ge Hong(Department of Radiation Oncology, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008,China)
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2019年第3期188-192,共5页
Chinese Journal of Radiation Oncology
基金
河南省科技开放合作项目(182106000062)
国家自然科学基金面上项目(81372436).